Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Hudson Valley Investment Advisors Inc. ADV

Hudson Valley Investment Advisors Inc. ADV decreased its position in Illumina, Inc. (NASDAQ:ILMN) by 1.1% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 17,145 shares of the life sciences company’s stock after selling 199 shares during the quarter. Hudson Valley Investment Advisors Inc. ADV’s holdings in Illumina were worth $2,291,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ILMN. Primecap Management Co. CA lifted its holdings in shares of Illumina by 462.5% during the 2nd quarter. Primecap Management Co. CA now owns 2,428,760 shares of the life sciences company’s stock worth $253,514,000 after acquiring an additional 1,997,010 shares during the period. Millennium Management LLC grew its holdings in Illumina by 305.0% in the second quarter. Millennium Management LLC now owns 1,485,599 shares of the life sciences company’s stock valued at $155,067,000 after purchasing an additional 1,118,747 shares during the period. Marshall Wace LLP acquired a new position in Illumina during the second quarter worth approximately $77,628,000. Massachusetts Financial Services Co. MA raised its stake in Illumina by 148.6% during the third quarter. Massachusetts Financial Services Co. MA now owns 1,056,172 shares of the life sciences company’s stock worth $137,735,000 after purchasing an additional 631,294 shares during the period. Finally, Janus Henderson Group PLC boosted its holdings in shares of Illumina by 40.5% in the 3rd quarter. Janus Henderson Group PLC now owns 2,168,057 shares of the life sciences company’s stock valued at $282,735,000 after purchasing an additional 625,245 shares during the last quarter. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently commented on ILMN. Barclays upped their price objective on Illumina from $135.00 to $145.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 5th. Citigroup downgraded Illumina from a “buy” rating to a “neutral” rating and lowered their price target for the company from $190.00 to $165.00 in a research report on Wednesday, December 11th. UBS Group raised their price objective on Illumina from $133.00 to $145.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Stephens boosted their target price on Illumina from $170.00 to $184.00 and gave the stock an “overweight” rating in a report on Tuesday, November 12th. Finally, Royal Bank of Canada increased their target price on shares of Illumina from $252.00 to $254.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 5th. Eight research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $165.95.

Illumina Trading Up 0.4 %

NASDAQ:ILMN opened at $139.68 on Friday. The stock has a market cap of $22.15 billion, a price-to-earnings ratio of -14.02 and a beta of 1.11. Illumina, Inc. has a one year low of $100.08 and a one year high of $156.66. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43. The business’s 50-day simple moving average is $141.37 and its 200 day simple moving average is $132.08.

Illumina (NASDAQ:ILMN) last announced its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.88 by $0.26. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The company had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.08 billion. During the same period in the prior year, the company posted $0.33 EPS. Illumina’s quarterly revenue was down 3.5% on a year-over-year basis. As a group, sell-side analysts predict that Illumina, Inc. will post 4.11 earnings per share for the current fiscal year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.